Format

Send to

Choose Destination
Cell Cycle. 2009 Feb 15;8(4):567-72. Epub 2009 Feb 18.

Not all substrates are treated equally: implications for mTOR, rapamycin-resistance and cancer therapy.

Author information

1
Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.

Abstract

The mTORC1 signaling pathway is a critical regulator of cell growth and is hyper activated in many different cancers. Rapamycin, an allosteric inhibitor of mTORC1, has been approved for treatment against renal cell carcinomas and is being evaluated for other cancers. Mechanistically, mTORC1 controls cell growth in part through its two well-characterized substrates S6K1 and 4E-BP1. In this review, we discuss the implications of a recent finding that showed differential inhibition of S6K1 and 4E-BP1 by rapamycin, leading to cell-type-specific repression of cap-dependent translation. We discuss potential mechanisms for this effect, and propose that mTOR-specific kinase inhibitors, instead of rapamycin, should be considered for mTOR-targeted cancer therapy.

PMID:
19197153
DOI:
10.4161/cc.8.4.7659
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center